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Abstract
Background: Berberine, an isoquinoline derivative alkaloid, has a wide range of pharmacological properties and is
considered to have anti-inflammatory and neuroprotective effects. However, there are no reports about the effects and
mechanisms of berberine in experimental autoimmune encephalomyelitis (EAE), an established model of multiple sclerosis
(MS).
Methodology/Principal Findings: Female C57 BL/6 mice immunized with myelin oligodendrocyte glycoprotein 35–55
amino acid peptide were treated with berberine at the day of disease onset and medication was administered daily until
mice were sacrificed. Blood–brain barrier (BBB) permeability and the alteration of matrix metalloproteinase-2 (MMP-2,
72 kDa) and matrix metalloproteinase-9 (MMP-9, 92 kDa) in the brain and cerebrospinal fluid (CSF) of EAE mice were
detected by quantitative measurement for Evan’s blue (EB) content, Western blot and gelatin zymography respectively. The
results showed that berberine attenuated clinical and pathological parameters of EAE, reduced the permeability of BBB,
inhibited the activity and expression of MMP-9 but not MMP-2 in the CSF and brain of EAE mice.
Conclusions/Significance: These findings suggest that berberine is effective to attenuate the clinical severity of EAE in C57
BL/6 mice by reducing the permeability of BBB, decreasing the expression and activity of MMP-9, and decreasing the
inflammatory infiltration. We think that berberine might be a potential therapeutic agent for MS.
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Introduction
Multiple Sclerosis (MS) is a chronic inflammatory demyelinating
autoimmune disease of the central nervous system (CNS) which
classically exhibits a relapsing- remitting course with increasing
neurological sequelae [1]. Experimental autoimmune encephalo-
myelitis (EAE), a T-cell-mediated model of autoimmune demye-
lination of the CNS, is an established model of MS that has been
utilized to test novel therapies [2]. Dysfunction of the blood–brain
barrier (BBB) and migration of T lymphocytes into the CNS are
the hallmarks in the pathogenesis of MS and EAE [3]. The entry
of leukocytes into the CNS is dependent on several factors, most
likely including the expression of matrix metalloproteinases
(MMPs) [4,5].
Berberine is an isoquinoline derivative alkaloid isolated from
many medicinal herbs, such as Hydrastis canadensis (goldenseal),
Cortex phellodendri (Huangbai) and Rhizoma coptidis (Huan-
glian) [6]. It is frequently utilized in proprietary Chinese herbal
drugs to treat inflammation, especially in the oral cavity [7].
Besides its anti-inflammation effects, many other pharmacological
benefits of berberine have also been reported including anti-
oxidation, anti-tumor and neuroprotective effects [8–12], but these
effects were strongly correlated with its anti-inflammatory
properties [7,11]. It has been reported that berberine could play
its anti-inflammatory effects through inhibiting the production of
tumor necrosis factor-a (TNF-a), interleukin-6 (IL-6) and mono-
cyte chemoattractant protein 1 (MCP-1), suppressing cyclooxy-
genase-2 (COX-2) expression, retarding prostaglandin E2 (PGE2)
production and exudates formation, and down-regulating the
expression of matrix metalloproteinase-2 (MMP-2) and matrix
metalloproteinase-9 (MMP-9) through mitogen-activated protein
kinase (MAPK) and nuclear factor-kB (NF-kB) signaling pathways
[7,13,14,15]. However, there are no reports about the effects of
berberine on the immune inflammatory diseases of CNS, such as
MS.
In this study, we tested whether berberine was effective to
ameliorate the clinical severity in C57 BL/6 EAE mice induced by
myelin oligodendrocyte glycoprotein 35–55 amino acid peptide
(MOG35–55). We further investigated the permeability of BBB
and the alteration of MMP-2 (72 kDa) and MMP-9 (92 kDa) in
the cerebrospinal fluid (CSF) and the brain of EAE mice. Our
results demonstrated that berberine could attenuate clinical and
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inhibit the activity and expression of MMP-9 but not MMP-2 in
the CSF and brain in EAE mice.
Results
Berberine ameliorated clinical severity of EAE mice
EAE was induced in six to eight-week-old female C57 BL/6
mice by immunization with MOG 35-55 as previously described
[16]. Berberine was intragastric administration via per os and the
therapy was started at the disease onset and medication was
administered daily until mice were sacrificed at day 35 post
immunization (p.i.). We found that the day of disease manifesta-
tion and the severity of symptoms at disease manifestation were
similar in the phosphate buffered saline (PBS)-treated and
berberine-treated groups (each group has seven animals, Fig. 1A).
The maximal score (maximum severity of disease in individual
mouse) of PBS- and berebrine-treated EAE mice were 3.4360.22
and 2.1060.22 respectively. The cumulative score (cumulative
disease severity) of PBS- and berbreine-treated EAE mice were
41.5063.75 and 18.3662.83 respectively. The maximal score and
the cumulative score were significantly reduced in berberine-
treated EAE mice (P,0.01, Fig. 1 B,C).
Berberine improved neuropathology of EAE mice
We next evaluated the lumbar spinal cords for pathological
changes in EAE mice following different treatments on day 20 p.i..
Hematoxylin and eosin staining and solochrome cyanin staining
were performed for evaluating inflammatory infiltration and
demyelination respectively. Histological scores of the degree of
inflammation and demyelination in the lumbar spinal cord of each
animal were evaluated blindly, using a semiquantitative system as
previously described [17–20].The inflammatory scores which
indicated the diffuse infiltration by mixed macrophages, T and
B lymphocytes into CNS white matter in the lumbar spinal cords
of the PBS- and berberine-treated EAE mice were 2.6760.17 and
1.5060.18 respectively. Compared with PBS-treated EAE mice,
berberine treatment drastically reduced inflammatory cell infiltra-
tion in EAE mice (P,0.01, Fig. 2). Solochrome cyanin staining
showed the demyelinating scores of the PBS- and berberine-
treated EAE mice were 2.8360.21 and 1.8360.20 respectively.
The demyelination in the lumbar spinal cords of EAE mice was
profoundly ameliorated by berberine treatment when compared
with PBS treatment (P,0.01, Fig. 2). The representative sections
depicting the inflammatory infiltrates and demyelination in the
lumbar spinal cords of EAE mice treated by PBS and berberine
were showed in Fig 3. Inflammatory infiltrates were widespread in
the PBS-treated mice at day 20 p.i. (Fig. 3A) but reduced in
berberine-treated mice (Fig. 3C). And a large plaque of
demyelination was seen in the PBS-treated EAE mice at day 20
p.i. (Fig. 3B), but in the berberine-treated EAE mice, demyelin-
ation was markedly attenuated (Fig. 3D).
Berberine reduced BBB dysfunction in EAE mice
The integrity of BBB of different treated animals was detected
by quantitative measurement for EB content at day 20 p.i.(n=6).
30 minutes after the intravenous injection of EB, animals were
carefully perfused to remove excess dye and the content of EB in
the brain tissue was measured at 610 nm using a spectrophotom-
eter. The concentrations of extravasated EB (expressed as
micrograms per gram of brain tissue) of different groups are
shown in Fig. 4. In the control mice, baseline level of EB was
70.3163.54 mg/g brain tissue. The content of EB in the brain of
PBS- and berberine-treated EAE mice were 196.7063.76 and
130.7565.61 mg/g brain tissue, respectively. Both PBS- and
berberine-treated EAE mice showed a significant increase in the
content of EB in the brain when compared with the control mice
(P,0.01). But the increase in the content of EB in the brain of
berberine-treated EAE mice was not as remarkable as that of the
PBS-treated EAE mice (P,0.01). The results showed that
berebrine could prevent further injury of BBB permeability.
Berberine down-regulated the expression of MMP-9 but
not MMP-2 in the brain of EAE mice
The brains of control mice, PBS- and berebrine-treated EAE
mice were obtained at day 20 p.i. (n=7). The expression of MMP-
2 and MMP-9 in the brains of different treated mice were detected
by Western blot. The bands were quantified with the Quantity one
Figure 1. The clinical course of EAE was attenuated by
berberine treatment. Daily clinical score (A), maximal score (B) and
cumulative score (C) of the PBS- and berberine-treated EAE mice. EAE
was induced in female C57 BL/6 mice with MOG 35-55 and treatment
with berberine was performed as described under materials and
methods. Each group had seven animals. Drug treatments were started
from the day of disease onset. Values represent the mean6S.E.M.,
**P,0.01 vs. PBS-treated EAE mice.
doi:10.1371/journal.pone.0013489.g001
Berberine; EAE; BBB
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MMP-9 expression in the brain of PBS-treated EAE mice was
recorded compared with that of the control mice (P,0.01). The
increase of MMP-9 was significantly attenuated in animals treated
with berberine when compared with PBS (P,0.01). However, the
expression of MMP-2 in the brain of PBS- and berberine-treated
EAE mice didn’t show significant difference. (P.0.05, Fig. 5).
Berberine inhibited MMP-9 activity but not MMP-2 in CSF
CSF of control mice, PBS- and berebrine-treated EAE mice
were obtained by puncture of the cisternamagna (n=7). To
determine the activities of MMP-2 and MMP-9 in CSF,
zymography was performed. The changes in MMP-2 and
MMP-9 activity were well in line with the expression of protein
in the brain. There was a marked increase of MMP-2 and MMP-9
activity in CSF in PBS-treated EAE mice compared to the control
mice (P,0.05 for MMP-2 and P,0.01 for MMP-9, respectively).
Treatment with berberine reduced MMP-9 zymographic activity
in CSF compared to PBS-treated EAE mice (P,0.01). There was
not significantly difference of the activity of MMP-2 between the
PBS- and berberine-treated EAE mice. (P.0.05, Fig. 6).
Discussion
Berberine has been used in the treatment of various infectious
disorders in Chinese traditional medicine for more than 3000
years. However, little is known about the effects of berberine on
immune inflammatory diseases such as EAE, an established model
of MS. In this study, we observed that oral berberine
administration initiated at the disease onset is effective to reduce
the severity of EAE in C57 BL/6 mice. Within the first 3 days of
berberine treatment, the neurological deficits were stabilized and
clinical scores of berberine-treated EAE mice were significantly
lower in comparison to the PBS-treated EAE mice. And the
inflammatory infiltration and demyelination in the lumbar spinal
cords of EAE mice were ameliorated by berberine treatment.
These results show berberine treatment is effective to reduce the
severity of EAE in C57 BL/6 mice either when evaluated clinically
or by neuropathological criteria.
We also found the permeability of BBB increased in PBS-
treated EAE mice, which coincided with previous reports [21–23].
Enhanced BBB permeability accompanying with large numbers of
leucocytes infiltrating into CNS plays an important role in the
development and progression of MS and EAE [24]. Transport
studies using radiolabeled mannitol as a marker for the transport
of compounds across the BBB revealed a 2-fold increase of
transport at day 14 p.i., when the clinical signs of EAE were most
abundant [25]. And various animal studies on EAE suggested that
the disease severity could be correlated with alteration of BBB
integrity, whereas limitation of the disease could be achieved by
preventing BBB alterations in EAE [26,27]. In our experiment,
berberine treatment reduced the permeability of BBB. Reduced
BBB permeability may suggest decreased leukocyte infiltration into
CNS then consequently reduced CNS inflammation, which was in
coincidence with the results of our histological evaluation in
berberine-treated EAE mice.
In MS, large numbers of leucocytes infiltrate through BBB to
the CNS in the absence of any apparent infection to produce
widespread tissue insult [23,28]. BBB permeability has been well
documented to be increased by MMPs, which control cell
migration across the BBB by disrupting the subendothelial
basement membrane and other components of the extracellular
matrix and eventually affecting tissue destruction in MS [4,29].
Among MMPs, in particular the gelatinases MMP-2 and MMP-9
seem to be involved in mechanisms of T cell migration into the
CNS and the disruption of the BBB [4,5]. MMP-2 and MMP-9
are secreted as proenzymes (72 kDa and 92 kDa for MMP-2 and
MMP-9 respectively) into the extracellular matrix, in which they
are then activated by proteolytic cleavage of the amino-terminal
domain (65 kDa and 84 kDa for MMP-2 and MMP-9 respective-
ly) [30–32]. MMP-2 is a constitutively expressed in the latent form
(72 kDa) and it is normally present in brain tissue and CSF [33].
Because of its tight association with extracellular matrix proteins,
CSF 84 kDa active form of MMP-9 has been found by
zymography only in a small proportion of MS [31], and active
MMP-9 may have been present in the 92-kDa band because a
latent metalloproteinase enzyme can be transformed into an active
configuration without autocleavage of its propeptide domain, and
the 84-kDa active form of MMP-9 could be coupled with
increased 92- kDa gelatinolytic band intensity [31,34,35]. So
MMP-2 and MMP-9, both in latent form, can be easily detected in
the brain and CSF, and can specifically degrade type IV collagen,
a key structural component of the basement membrane that
surrounds blood vessels which induces the destruction of BBB
[30,31,36].
In our experiment, we found the expression of MMP-2 and
MMP-9, both in latent form, increased in the brain of PBS-treated
EAE mice, and the changes in MMP-2 and MMP-9 activity in
CSF were well in line with the expression of protein, which are
coincided with previous reports [37]. Berberine treatment
decreased the activity and expression of MMP-9 but not MMP-
2 in the brain and CSF in our experiment. The results were not
much coincided with previous reports. It has been demonstrated
that berberine could suppress the MMP-2 expression in A 547 cells
(a human non-small cell lung cancer cells with a highly metastatic
capability) and inhibit MMP-9 expression in phorbol 12-myristate
13-acetate (PMA)-induced macrophages[10,38], and berberine
also could suppress migration and invasion of human SCC-4
tongue squamous cancer cells through the inhibition of MMP-2
and MMP-9 [15]. That is, berebrine could inhibit both MMP-2
and MMP-9 expression in vitro.
The possible explanation for this discrepancy may be that
berberine could produce different effects on MMPs in different
pathological conditions. In vivo, MMP-2 is constitutively
expressed and found in healthy brain and CSF, and this constraint
Figure 2. Berberine treatment decreased inflammation and
demyelination in the lumbar spinal cord of EAE mice. Mice were
subjected to histopathological assay at day 20 p.i.. Each group had six
animals. Consecutive sections were analyzed for hematoxylin and eosin
staining and solochrome cyanin staining to detect inflammatory
infiltration and demyelination respectively. Values represent the
mean6S.E.M., **P,0.01 vs. PBS-treated EAE mice.
doi:10.1371/journal.pone.0013489.g002
Berberine; EAE; BBB
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[39]. However, MMP-9 is normally present at low concentrations,
but rapidly increases in quantity to inflammatory stimuli such as
EAE. Further more, MMP-9 is secreted into the extracellular
space where it can move around freely, causes more extensive
damage to the injury site of BBB [39]. Athough both MMP-2 and
MMP-9 were involved in mechanisms of T cell migration into the
CNS and the disruption of the BBB [30,31], the predominant
production of MMP-9 in the brain and CSF may be more effective
in correlation with BBB injury in vivo while MMP-2 only exhibits
a low responsiveness to inflammatory stimuli [40,41].
It has been reported that direct injection of MMP-9 into the
brain of rats induced BBB breakdown and loss of myelin staining,
both of which are typical features of MS [42]. And MMP-9
activity is associated with short duration relapsing and active
disease [29,43]. MMP-9-null mice exhibit decrease of the severity
of EAE [44]. However, researchers found that binding of T cells to
endothelial cells could induce the expression of MMP-2 [45],
particularly during the repairing processes. MMP-2 may prevail by
remodeling the extracellular matrix, which may correspond with
the chronic progressive stage of MS [29]. And MMP-2-null mice
exhibit severer EAE with enhanced lymphocyte transmigration
[46]. As a plant ingredient with anti-inflammatory effects, bererine
probably achieves the effect through the decrease of the expression
of MMP-9. Because an overexpression of MMP-2 could be
protective in remodeling the extracellular matrix and promote
tissue repair [45,46], the benefit of berberine also may partly came
from the MMP-2, because MMP-2 has not been reduced by
berebrine treatment in our study.
Our results demonstrated that berberine could reduce the
permeability of BBB and suppress the increased expression of
MMP-9 in the brain and CSF of EAE mice. Since predominant
Figure 3. The representative sections depicting the inflammation and demyelination in the lumbar spinal cord of EAE mice by PBS
and berberine treatment. Inflammatory infiltration was widespread in the PBS-treated EAE mice (A), but which was attenuated by berberine
treatment (B). A large plaque of demyelination was seen in the PBS-treated EAE mice (C), and demyelination was attenuated in berberine-treated EAE
mice (D). a-d were higher magnification views of the boxed areas in A, B, C and D, respectively. A-D: 640; a-d: 6400.
doi:10.1371/journal.pone.0013489.g003
Berberine; EAE; BBB
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MMP-9 might be pathologically involved in the disruption of the
vascular basement membranes and the BBB, paving the way for
infiltrating cells of the immune system [30], we can tentatively
suggest that the protectetive effect of berberine on BBB is
associated with a down-regulation of MMP-9 expression and then
the inhibition of leucocytes infiltrating into CNS. However,
recently research found that berberine can exert immunosuppres-
sive effect through inhibiting the activation and proliferation of T
cells in healthy human beings [47]. Whether berberine may have
direct effects on lymphocytes or other leukocytes in EAE mice
need further explore. And more studies should be taken to uncover
the other mechanisms by which berebrine could improve the EAE.
Our data demonstrate that berberine is effective to attenuate the
clinical severity of EAE mice. Through decreasing the expression
and activity of MMP-9, berberine could protect the integrity of
BBB and decrease the inflammatory infiltration. These findings
suggest berberine might be a potential therapeutic agent for MS.
Materials and Methods
Animals and Regents
Six to eight-week-old female C57 BL/6 mice weighting 16 to 18
g were obtained from the Experimental Animal Center of Sun
Yat-sen University (Guangzhou, China). Experiments were carried
out according to the National Institutes of Health Guide for Care
and Use of Laboratory Animals and were approved by the
Bioethics Committee of Sun Yat-sen University. Berberine and
complete Freund’s adjuvant (CFA) were purchased from Sigma-
Aldrich (St. Louis, MO). MOG35–55 peptide (MEVG-
WYRSPFSRVVHLYRNGK) was synthesized by CL. Bio-Scien-
tific CO., LTD. (Xi’an, China). Amino acid sequences were
confirmed by amino acid analysis and mass spectroscopy. The
purity of the peptide was greater than 95%. Mycobacterium
tuberculosis H37RA was purchased from Difco (Detroit, MI).
Pertussis toxin (PTX) was purchased from Alexis Corp (San Diego,
CA). Monoclonal anti-MMP-2 and polyclonal anti-MMP-9 were
purchased from Thermo Fisher Scientific (CA, USA) and Abcam
(MA, USA) respectively.
Figure 4. The effect of berberine on brain BBB permeability in
EAE mice. The integrity of BBB was detected by quantitative
measurement for EB content at day 20 p.i. in six animals per group.
EB is expressed as micrograms per gram of brain tissue against a
standard curve. Values represent the mean6S.E.M., ** P,0.01 vs.
control mice,
##P,0.01 vs. PBS-treated EAE mice.
doi:10.1371/journal.pone.0013489.g004
Figure 5. Effects of berberine on the expression of MMP-2 and MMP-9 in the brain of different treated mice. The brains from different
treated mice were harvested for Western blot at day 20 p.i.. Each group had seven animals. Values represent the mean6 S.E.M., **P,0.01 vs control
mice,
##P,0.01, vs PBS-treated EAE mice.
doi:10.1371/journal.pone.0013489.g005
Berberine; EAE; BBB
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EAE was induced in six to eight-week-old female C57 BL/6
mice by the procedure which had been described previously [16].
Briefly, mice were immunized subcutaneously in the flanks with
200 mg of MOG35-55 peptide per animal emulsified in complete
Freund’s adjuvant (CFA) containing 500 mg of Mycobacterium
tuberculosis H37RA. Immediately thereafter, and again 48 h later,
the mice received an intraperitoneal injection of 300 ng of
Pertussix toxin in 100 ml of PBS. An additional injection of
MOG35–55 peptide in CFA was delivered 7 days later. The
animals were examined daily for disability. Clinical scores were
defined as follows: 0, no signs; 1, loss of tail tonicity; 2, flaccid tail;
3, ataxia and/or paresis of hindlimbs; 4, complete paralysis of
hindlimbs; 5, moribund or death. The maximum disease score was
achieved by each mouse over the course of the entire experiment.
The overall disease burden of each mouse was represented as the
cumulative disease severity, which was the sum of the disability
scores obtained daily over the course of the 35-day experiment.
Treatment of mice
Mice were randomly assigned to three groups: control mice,
PBS-treated EAE mice, berberine-treated EAE mice. Each group
has seven animals and every experiment was repeated three times.
The dose of berberine was chosen on the basis of previous in-vivo
data and our preliminary dose-finding experiment [48,49,50].
Berberine was dissolved in PBS and was intragastric administra-
tion via per os (p.o.) using a 20 ga straight oral gavage needle for
mice at a dose of 30 mg/kg to EAE mice. PBS-treated EAE mice
were intragastric administration PBS only. Treatment was
initiated at the disease onset and medication was administered
daily until mice were sacrificed at day 35 p.i.. To evaluate the
treatment effects, the lumbar spinal cords of different treated EAE
mice were subjected to histopathology assay. The integrity of BBB
was detected by quantitative measurement for EB content. CSF
was obtained by puncture of the cisternamagna to detect
gelatinase activity and brains of different treated mice were
prepared for Western blot to determine the expression of MMP-2
and MMP-9 at day 20 p.i..
Histological evaluation
Histological evaluation was performed on paraformaldehyde
fixed, paraffin-embedded sections of lumbar spinal cords of
different treated EAE mice (n=6). Paraffin sections were stained
with hematoxylin and eosin and solochrome cyanin impregnation
for evaluating inflammatory infiltration and demyelination
respectively. Histopathological examination was performed in a
blinded fashion. The scale evaluated for inflammation was as
follows [17,18]: 0, no inflammatory cells; 1, a few scattered
inflammatory cells; 2, organisation of inflammatory infiltrates
around blood vessels; 3, extensive perivascular cuffing with
extension into adjacent parenchyma, or parenchymal infiltration
without obvious cuffing. Demyelination in the spinal cords was
scored as previously described [19,20]: 1, traces of subpial
demyelination; 2, marked subpial and perivascular demyelination;
3, confluent perivascular or subpial demyelination; 4, massive
perivascular and subpial demyelination involving one half of the
spinal cord with presence of cellular infiltrates into CNS
parenchyma; 5, extensive perivascular and subpial demyelination
involving the whole cord section with presence of cellular
infiltrates into CNS parenchyma.
Evaluation of BBB disruption
The integrity of BBB was detected by quantitative measurement
for EB content at day 20 p.i. in six animals per group [51,52].
Sterilized 2% EB (Sigma, USA) solution was administered
intravenously at a dosage of 4 ml/kg per animal. 30 minutes
after injection, mice were perfused with saline to remove
intravascular EB dye. Brains were rapidly removed and each
sample was weighed and then homogenized with 2.5 ml PBS and
mixed with 2.5 ml 60% trichloroacetic acid to precipitate protein.
Figure 6. The gelatinolytic activities of MMP-2 and MMP-9 in the CSF of different treated mice. CSF was obtained by puncture of the
cisternamagna to detect gelatinase activity at day 20 p.i.. Each group had seven animals. Values represent the mean6 S.E.M., **P,0.01, *P,0.05 vs
control mice,
##P,0.01 vs PBS-treated EAE mice.
doi:10.1371/journal.pone.0013489.g006
Berberine; EAE; BBB
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supernatants were measured at 610 nm for absorbance of EB by
using a spectrophotometer (Genesis 10uv; Thermo Electron
Corporation, Madison, WI). EB is expressed as micrograms per
gram of brain tissue against a standard curve.
Western blot
To investigate the protein expression of MMP-2 and MMP-9 in
the brains of the control mice, PBS- and berberine-treated EAE
mice, we performed Western blot analysis. Samples of the brain
from different treated mice were loaded on 10% gradient sodium
dodecyl sulfate-polyacrylamide gels (20 mg protein per lane).
Proteins were transferred onto nitrocellulose membrane (Bio-
Rad). The membranes were blocked by 5% non-fat milk.
Afterward, the membranes were incubated with monoclonal
anti-MMP-2 (1:600) and polyclonal anti-MMP-9 (1:400) overnight
respectively. After 3 times washes with TBST buffer, the
membrane was incubated with anti-mouse-HRP and goat anti-
rabbit-HRP for 30 minuates, respectively. The experiment was
repeated in triplicate and b-actin was used as internal control. The
bands were quantified with the Quantity one image analysis
software.
Gelatinase activity detection
Gelatinase activity of MMP-2 and MMP-9 in CSF was
measured by sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis zymography (SDS-PAGE) [53,54]. After quantified with
bicinchoninic acid assay (BCA) method, 10 mg of total proteins
were used for each sample. A protein marker standard was used to
identify molecular weights. The electrophoresis was carried out at
20 mA constant current for 2 h under non-reducing conditions in
10% polyacrylamide-SDS gels containing 1 mg/ml gelatin as the
proteinase substrate [55]. The gel was washed in 50 ml of 2.5%
Triton X-100 twice for 30 minutes at room temperature to remove
SDS and then incubated in enzyme buffer containing CaCl2-Tris-
NaCl for 24 h at 37uC to allow proteolysis of the gelatin substrate,
fixed, and stained with Coomassie blue. The bands were
quantified by densitometric analysis with Quantity one software.
Statistical analysis
Data are expressed as means6S.E.M. and analyzed by SPSS
13.0 software. Differences between clinical scores and histological
scores were analyzed with Mann-Whitney tests. Differences
between gelatinase activity, protein levels and EB content were
analyzed with One-Way ANOVA followed by Bofferroni’s post
hoc tests. P values less than 0.05 were considered statistically
significant.
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